Científicos israelíes lanzan el primer ensayo clínico mundial para un tratamiento experimental contra el cáncer de páncreas
El tratamiento desarrollado en Israel utiliza moléculas de ARN para silenciar genes KRAS mutados y se probará junto con la terapia estándar en pacientes con enfermedad localmente avanzada.
Valoración
A new clinical trial in Israel targets pancreatic cancer by using RNA molecules to disable mutated KRAS genes, a common driver of the disease. The treatment will be tested alongside standard therapy in patients whose cancer has not yet spread widely. Success could open a novel therapeutic pathway for one of the most lethal cancers, where treatment options are limited. The trial's early results will be closely watched by the oncology community.